针对这些发现,23andMe在一份声明中表示:“竞争对手声称我们正将‘临床假阴性结果’退回是假消息,其对本公司测试的特征描述也是错误的。我们的测试非常准确。作为FDA授权检测过程的一部分,我们已经证明,我们的健康产品基因变异测试准确性超过99%。”
The company said it makes clear to customers that it tests only for certain genetic variants and that customers should not forgo any recommended testing based on 23andMe results. "23andMe is not a diagnostic test," the company said. "If an individual has a family history of cancer or other indications for clinical testing we always recommend consulting a healthcare provider first."
该公司表示,已向客户明确表示,只检测某些基因变异,客户不应放弃任何基于23andMe结果的推荐检测。该公司表示:“这不是诊断测试。如果一个人有癌症家族史或其他临床检测的适应症,我们一直建议首先咨询医疗机构。”
Prof Anneke Lucassen, a clinical geneticist at the University of Southampton, said that, in her experience, non-specialists would be likely to wrongly interpret negative results as an "all-clear".
南安普顿大学临床遗传学家安妮克·卢卡森教授表示,根据她的经验,非专业人士很可能会错误地将阴性结果解读为“没有风险”。
"I do think the 'false-negative' rate is an issue, not necessarily through the companies' fault but through low general awareness," she said. "Most people who come to clinic ask: 'Have I got the gene for breast cancer?' and imagine it's a single test, not that the test involves looking through around 20,000 letters of the genetic code to see if any one of them might be different."
【基因检测结果呈阴性可能是"虚假的安慰"】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15